Advertisement

---

GLAXOSMITHKLINE

100 GlaxoSmithKline employees embark on global and local long-term volunteer assignments

[2013-06-26] - - PULSE Volunteer Partnership helps build healthy communities by sharing corporate expertise and skills with nonprofits such as Save the Children


Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies

[2013-05-29] - - Both approved for unresectable or metastatic melanoma with BRAF V600E mutation; Mekinist also approved for BRAF V600K mutation


BREO™ ELLIPTA™ gains US approval for the treatment of COPD

[2013-05-10] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers